Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability

Murdoch Childrens Research Institute132 enrolled

Overview

This is a multi-site, double-blind, parallel group, randomized, placebo-controlled study of 140 participants comparing oral purified cannabidiol isolate (CBD) with placebo in reducing Severe Behavioral Problems (SBP) at 8 weeks in children aged 6 - 18 years with Intellectual Disability (ID). Eligible participants will be randomized 1:1 to receive either CBD or placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

132

Conditions

Intellectual Disability Child Behavior Problem

Interventions

Cannabidiol OilDRUG

Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma

PlaceboDRUG

MCT oil and flavoring solution, also manufactured by THC Pharma

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Males and females aged 6 - 18 years of age; 2. DSM-5 diagnosis of intellectual disability (ID): 1. Full scale IQ \< 70 on standardized cognitive assessment. Testing results must be sighted by the investigators and performed within two years of enrollment. In the event that records of prior testing are unavailable or the assessment was more than 2 years prior, IQ will be estimated using the Wechsler Abbreviated Scale of Intelligence-II. 2. Deficit in adaptive function (basis for severity rating of ID in DSM-5) in at least one activity of life on the Vineland Adaptive Behavior Scales (derives scores in Communication, Daily Living Skills and Socialization domains, and a Global Adaptive score). If records of prior testing are unavailable or the assessment was more than 2 years prior, this will be completed by the parent or guardian. 3. SBP: Defined as scores of: 1. 18 or higher on the Aberrant Behavior Checklist-Irritability subscale (ABC-I), and 2. moderate or higher on the Clinical Global Impressions-Severity scale; 4. No changes in either medication or other interventions in the 4 weeks prior to randomization, and intention to remain on same dose for the duration of the study; 5. Written informed consent from parent or legal guardian; 6. Participant and family have the ability to comply with the protocol requirements, in the opinion of the investigator. Exclusion Criteria: 1. Non-English speaking parents; 2. Psychosis; 3. Taking clobazam, mTOR inhibitors (e.g sirolimus, tacrolimus), anti-cancer agents, citalopram \>20mg/day, escitalopram \>10mg/day.; 4. Abnormal liver function tests: defined as ALT \> twice ULN; 5. Abnormal renal function tests: defined as creatinine \> ULN 6. Current use of medicinal cannabis, or use in the 4 weeks prior to screening; 7. Pregnant or intending to become pregnant during the study, or breastfeeding; 8. Known allergy to cannabidiol or cannabis products

Locations (3)

The Children's Hospital at Westmead

Westmead, New South Wales, Australia

Monash Children's Hospital

Clayton, Victoria, Australia

Royal Children's Hospital / Murdoch Children's Research Institute

Parkville, Victoria, Australia

Outcomes

Primary Outcomes

Mean difference between the cannabidiol 100mg/ml and placebo arms on the Aberrant Behavior Checklist-Irritability (ABC-I) subscale total score at day 64

This is a 15 item parent-rated questionnaire, used to measure Severe Behavioral Problems in children